What is CardioMech?
CardioMech is a medical technology innovator dedicated to addressing the critical clinical needs of patients suffering from Mitral Regurgitation. The company's flagship development, the CardioMech MVRS, is engineered as a transcatheter mitral valve repair solution designed to provide a less invasive alternative to traditional open-heart surgery. By simplifying the procedural requirements for both surgical candidates and those deemed ineligible for conventional interventions, CardioMech aims to redefine the standard of care in structural heart disease. Currently, the technology remains in the investigational phase, with the company focusing on rigorous clinical validation to ensure safety and efficacy before commercialization.
How much funding has CardioMech raised?
CardioMech has raised a total of $36.5M across 3 funding rounds:
Debt
$5M
Series A
$18.5M
Other Financing Round
$13M
Debt (2019): $5M, investors not publicly disclosed
Series A (2020): $18.5M led by Investinor and Hadean Ventures
Other Financing Round (2024): $13M, investors not publicly disclosed
Key Investors in CardioMech
Investinor
Investinor AS is a prominent investment firm that partners with entrepreneurs and startups to scale promising businesses into global leaders, with a specific focus on sustainable innovation and early-stage venture development.
Hadean Ventures
Hadean Ventures is a specialized life sciences investment firm that provides capital and strategic guidance to companies developing breakthrough medical technologies and therapeutic solutions.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for CardioMech?
With the recent influx of capital, CardioMech is well-positioned to advance its clinical development programs and refine its transcatheter delivery systems. The strategic focus will likely center on navigating the complex regulatory pathways required for medical device approval while expanding its intellectual property portfolio. As the company transitions from the investigational stage toward potential clinical trials and eventual market entry, the emphasis will remain on demonstrating the superior clinical outcomes of the MVRS device. Future milestones will be defined by the successful completion of human trials and the establishment of robust manufacturing capabilities to support the anticipated demand for minimally invasive cardiovascular solutions.
See full CardioMech company page
